Browsing by Subject "Artemisinin-based combination therapy"
Now showing items 1-4 of 4
-
Development and evaluation of a solid oral dosage form for an artesunate and mefloquine drug combination
(2014)Malaria affects about forty percent of the world’s population. Annually more than 1.5 million fatalities due to malaria occur and parasite resistance to existing antimalarial drugs such as mefloquine has already reached ... -
Development and evaluation of an oral fixed–dose triple combination dosage form for artesunate, dapsone and proguanil
(North-West University, 2011)Malaria is a life–threatening disease caused by Plasmodium spp and causes over one million deaths annually. The complex life cycle of the malaria parasite offers several points of attack for the antimalarial drugs. The ... -
Development of lipid matrix tablets containing a double-fixed dose combination of artemether and lumefantrine
(North-West University (South-Africa), 2019)Malaria remains one of the most serious vector-borne and prominent life-threatening diseases in sub-Saharan Africa. Africa has the heaviest malarial disease burden in the world, accounting for 91% of the estimated 445 000 ... -
Trends in malaria case management following changes in the treatment policy to artemisinin combination therapy at the Mbakong Health Centre, Cameroon 2006-2012: a retrospective study
(Elsevier, 2015)National malaria treatment policies are devised to guide health professionals and to facilitate diagnosis and case management. Following the recommendations of the WHO, Cameroon changed its malaria treatment policy from ...